357 related articles for article (PubMed ID: 29923256)
1. Statins: a role in breast cancer therapy?
Borgquist S; Bjarnadottir O; Kimbung S; Ahern TP
J Intern Med; 2018 Oct; 284(4):346-357. PubMed ID: 29923256
[TBL] [Abstract][Full Text] [Related]
2. The Impact of Statin Therapy on the Survival of Patients with Gastrointestinal Cancer.
Gachpazan M; Kashani H; Khazaei M; Hassanian SM; Rezayi M; Asgharzadeh F; Ghayour-Mobarhan M; Ferns GA; Avan A
Curr Drug Targets; 2019; 20(7):738-747. PubMed ID: 30539694
[TBL] [Abstract][Full Text] [Related]
3. Targeting HMG-CoA reductase with statins in a window-of-opportunity breast cancer trial.
Bjarnadottir O; Romero Q; Bendahl PO; Jirström K; Rydén L; Loman N; Uhlén M; Johannesson H; Rose C; Grabau D; Borgquist S
Breast Cancer Res Treat; 2013 Apr; 138(2):499-508. PubMed ID: 23471651
[TBL] [Abstract][Full Text] [Related]
4. Induction of 3-hydroxy-3-methylglutaryl-CoA reductase mediates statin resistance in breast cancer cells.
Göbel A; Breining D; Rauner M; Hofbauer LC; Rachner TD
Cell Death Dis; 2019 Jan; 10(2):91. PubMed ID: 30692522
[TBL] [Abstract][Full Text] [Related]
5. The target for statins, HMG-CoA reductase, is expressed in ductal carcinoma-in situ and may predict patient response to radiotherapy.
Butt S; Butt T; Jirström K; Hartman L; Amini RM; Zhou W; Wärnberg F; Borgquist S
Ann Surg Oncol; 2014 Sep; 21(9):2911-9. PubMed ID: 24777857
[TBL] [Abstract][Full Text] [Related]
6. Statin drugs to reduce breast cancer recurrence and mortality.
Beckwitt CH; Brufsky A; Oltvai ZN; Wells A
Breast Cancer Res; 2018 Nov; 20(1):144. PubMed ID: 30458856
[TBL] [Abstract][Full Text] [Related]
7. Post-diagnostic statin use and its association with cancer recurrence and mortality in breast cancer patients: a systematic review and meta-analysis.
Jaiswal V; Agrawal V; Ang SP; Saleeb M; Ishak A; Hameed M; Rajak K; Kalra K; Jaiswal A
Eur Heart J Cardiovasc Pharmacother; 2023 Dec; 9(8):731-740. PubMed ID: 37562940
[TBL] [Abstract][Full Text] [Related]
8. Statins Use and Risk of Breast Cancer Recurrence and Death: A Systematic Review and Meta-Analysis of Observational Studies.
Mansourian M; Haghjooy-Javanmard S; Eshraghi A; Vaseghi G; Hayatshahi A; Thomas J
J Pharm Pharm Sci; 2016; 19(1):72-81. PubMed ID: 27096694
[TBL] [Abstract][Full Text] [Related]
9. Statins as anti-cancer therapy; Can we translate preclinical and epidemiologic data into clinical benefit?
Chae YK; Yousaf M; Malecek MK; Carneiro B; Chandra S; Kaplan J; Kalyan A; Sassano A; Platanias LC; Giles F
Discov Med; 2015 Dec; 20(112):413-27. PubMed ID: 26760985
[TBL] [Abstract][Full Text] [Related]
10. Statins as anti-tumor agents: A paradigm for repurposed drugs.
Tripathi S; Gupta E; Galande S
Cancer Rep (Hoboken); 2024 May; 7(5):e2078. PubMed ID: 38711272
[TBL] [Abstract][Full Text] [Related]
11. Therapy insight: Potential of statins for cancer chemoprevention and therapy.
Katz MS
Nat Clin Pract Oncol; 2005 Feb; 2(2):82-9. PubMed ID: 16264880
[TBL] [Abstract][Full Text] [Related]
12. The relationship between statins and breast cancer prognosis varies by statin type and exposure time: a meta-analysis.
Liu B; Yi Z; Guan X; Zeng YX; Ma F
Breast Cancer Res Treat; 2017 Jul; 164(1):1-11. PubMed ID: 28432513
[TBL] [Abstract][Full Text] [Related]
13. Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.
Evans M; Roberts A; Davies S; Rees A
Drugs; 2004; 64(11):1181-96. PubMed ID: 15161326
[TBL] [Abstract][Full Text] [Related]
14. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
15. Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and/or statins.
Chae YK; Valsecchi ME; Kim J; Bianchi AL; Khemasuwan D; Desai A; Tester W
Cancer Invest; 2011 Nov; 29(9):585-93. PubMed ID: 21936625
[TBL] [Abstract][Full Text] [Related]
16. Gene signature associated with resistance to fluvastatin chemoprevention for breast cancer.
Bhardwaj A; Embury MD; Ju Z; Wang J; Bedrosian I
BMC Cancer; 2022 Mar; 22(1):282. PubMed ID: 35296281
[TBL] [Abstract][Full Text] [Related]
17. Statins and breast cancer prognosis: evidence and opportunities.
Ahern TP; Lash TL; Damkier P; Christiansen PM; Cronin-Fenton DP
Lancet Oncol; 2014 Sep; 15(10):e461-8. PubMed ID: 25186049
[TBL] [Abstract][Full Text] [Related]
18. Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality.
Lim S; Sakuma I; Quon MJ; Koh KK
Int J Cardiol; 2013 Sep; 167(5):1696-702. PubMed ID: 23159411
[TBL] [Abstract][Full Text] [Related]
19. Targeting tumor cell metabolism with statins.
Clendening JW; Penn LZ
Oncogene; 2012 Nov; 31(48):4967-78. PubMed ID: 22310279
[TBL] [Abstract][Full Text] [Related]
20. The Potential of Isoprenoids in Adjuvant Cancer Therapy to Reduce Adverse Effects of Statins.
Mo H; Jeter R; Bachmann A; Yount ST; Shen CL; Yeganehjoo H
Front Pharmacol; 2018; 9():1515. PubMed ID: 30662405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
